Troy H. Guthrie

8.5k total citations · 4 hit papers
69 papers, 3.8k citations indexed

About

Troy H. Guthrie is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Troy H. Guthrie has authored 69 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 18 papers in Hematology and 16 papers in Genetics. Recurrent topics in Troy H. Guthrie's work include Cancer Treatment and Pharmacology (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Lymphoma Diagnosis and Treatment (9 papers). Troy H. Guthrie is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Lymphoma Diagnosis and Treatment (9 papers). Troy H. Guthrie collaborates with scholars based in United States, United Kingdom and Canada. Troy H. Guthrie's co-authors include Steven O’Day, Kevin M. Chin, L. Thomas, Gerald P. Linette, Jason Chesney, William Waterfield, Sylvie Négrier, Bart Neyns, Dirk Schadendorf and Célèste Lebbé and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Troy H. Guthrie

68 papers receiving 3.6k citations

Hit Papers

Ipilimumab monotherapy in patients with pretreated advanc... 2001 2026 2009 2017 2009 2016 2001 2006 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    2009 934 citations Jedd D. Wolchok, Bart Neyns et al. The Lancet Oncology profile →
  2. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
    2016 595 citations Troy H. Guthrie et al. profile →
  3. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
    2001 507 citations Gerald Batist, Gopal Ramakrishnan et al. Journal of Clinical Oncology profile →
  4. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer
    2006 500 citations Troy H. Guthrie et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Troy H. Guthrie United States 22 2.0k 908 779 776 727 69 3.8k
J. Thaler Austria 37 1.1k 0.6× 991 1.1× 365 0.5× 558 0.7× 512 0.7× 125 4.1k
Josef S. Smolen Austria 24 850 0.4× 1.7k 1.9× 302 0.4× 1.2k 1.5× 421 0.6× 37 5.3k
Yago Nieto United States 34 1.7k 0.9× 859 0.9× 229 0.3× 609 0.8× 644 0.9× 242 4.0k
Byron M. Espina United States 29 1.6k 0.8× 455 0.5× 333 0.4× 433 0.6× 330 0.5× 73 3.5k
Paul S. Ritch United States 38 2.9k 1.5× 625 0.7× 578 0.7× 315 0.4× 322 0.4× 133 4.6k
Mark Hertzberg Australia 28 1.7k 0.8× 330 0.4× 320 0.4× 605 0.8× 894 1.2× 166 3.5k
James A. Neidhart United States 27 1.5k 0.7× 672 0.7× 191 0.2× 805 1.0× 681 0.9× 75 3.5k
Sanford Kempin United States 33 1.1k 0.5× 759 0.8× 248 0.3× 658 0.8× 1.2k 1.7× 69 3.9k
Mustafa Beneklı Türkiye 24 1.2k 0.6× 623 0.7× 257 0.3× 291 0.4× 352 0.5× 182 2.6k
Ronald G. Stoller United States 27 2.0k 1.0× 920 1.0× 310 0.4× 192 0.2× 160 0.2× 63 3.5k

Countries citing papers authored by Troy H. Guthrie

Since Specialization
Citations

This map shows the geographic impact of Troy H. Guthrie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Troy H. Guthrie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Troy H. Guthrie more than expected).

Fields of papers citing papers by Troy H. Guthrie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Troy H. Guthrie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Troy H. Guthrie. The network helps show where Troy H. Guthrie may publish in the future.

Co-authorship network of co-authors of Troy H. Guthrie

This figure shows the co-authorship network connecting the top 25 collaborators of Troy H. Guthrie. A scholar is included among the top collaborators of Troy H. Guthrie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Troy H. Guthrie. Troy H. Guthrie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arkenau, H-T., Troy H. Guthrie, Tarek Mekhail, et al.. (2021). 643TiP Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors. Annals of Oncology. 32. S671–S672. 2 indexed citations
2.
Zodelava, Mamia, Troy H. Guthrie, Thomas Strack, et al.. (2020). A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology. 38(15_suppl). TPS8074–TPS8074. 3 indexed citations
3.
4.
Amin, Asim, David H. Lawson, April K.S. Salama, et al.. (2016). Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. Journal for ImmunoTherapy of Cancer. 4(1). 44–44. 51 indexed citations
5.
Yardley, Denise A., James A. Reeves, Elizabeth Claire Dees, et al.. (2016). Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clinical Breast Cancer. 16(6). 471–479.e1. 29 indexed citations
6.
Amin, Asim, David H. Lawson, April K.S. Salama, et al.. (2015). A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).. Journal of Clinical Oncology. 33(15_suppl). 9032–9032. 6 indexed citations
7.
Wolchok, Jedd D., Bart Neyns, Gerald P. Linette, et al.. (2009). Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology. 11(2). 155–164. 934 indexed citations breakdown →
8.
Kuter, David J., James B. Bussel, Adrian C. Newland, et al.. (2008). Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study. Blood. 112(11). 402–402. 13 indexed citations
9.
George, James N., Gary E. Raskob, Sara K. Vesely, et al.. (2003). Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti‐D with routine care. American Journal of Hematology. 74(3). 161–169. 49 indexed citations
10.
Batist, Gerald, Gopal Ramakrishnan, John Gutheil, et al.. (2001). Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer. Journal of Clinical Oncology. 19(5). 1444–1454. 507 indexed citations breakdown →
11.
Faillace, Walter J. & Troy H. Guthrie. (2000). Recovery from Cruciate Paralysis Due to Axial Subluxation from Metastatic Breast Carcinoma: A Case Report. The Breast Journal. 6(2). 139–142. 1 indexed citations
12.
Myers, Cynthia D., et al.. (1999). Adjunctive Approaches for Sickle Cell Chronic Pain. Complementary health practice review. 5(3). 203–212. 13 indexed citations
13.
Guthrie, Troy H., et al.. (1997). Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. American Journal of Hematology. 55(2). 55–58. 39 indexed citations
14.
15.
Guthrie, Troy H.. (1989). Treatable Carcinoma of Unknown Origin. The American Journal of the Medical Sciences. 298(2). 74–78. 5 indexed citations
16.
Guthrie, Troy H., et al.. (1988). Idiopathic Thrombocytopenic Purpura in the Older Adult Patient. The American Journal of the Medical Sciences. 296(1). 17–21. 39 indexed citations
17.
Guthrie, Troy H. & Hal G. Bingham. (1986). Cisplatin and doxorubicin. Plastic & Reconstructive Surgery. 77(3). 511–511. 3 indexed citations
18.
19.
Guthrie, Troy H., et al.. (1985). Acute Deafness: A Complication of High-Dose Cisplatin. Archives of Otolaryngology - Head and Neck Surgery. 111(5). 344–345. 12 indexed citations
20.
Guthrie, Troy H. & Edward S. Porubsky. (1982). Successful systemic chemotherapy of advanced squamous and basal cell carcinoma of the skin with cis‐diamminedichloroplatinum iii and doxorubicin. The Laryngoscope. 92(11). 1298–1299. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Thaler Breakdown of academic impact, for papers by Josef S. Smolen Breakdown of academic impact, for papers by Yago Nieto Breakdown of academic impact, for papers by Byron M. Espina Breakdown of academic impact, for papers by Paul S. Ritch Breakdown of academic impact, for papers by Mark Hertzberg Breakdown of academic impact, for papers by James A. Neidhart Breakdown of academic impact, for papers by Sanford Kempin Breakdown of academic impact, for papers by Mustafa Beneklı Breakdown of academic impact, for papers by Ronald G. Stoller
Rankless by CCL
2026